Variantyx at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Variantyx at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
V Variantyx Framingham, Massachusetts	1 VP Product
LinkedIn Private company Variantyx provides whole-genome-based diagnostic and screening tests for rare disorders, reproductive genetics, hereditary cancer, and wellness. Launched two new germline assays for hematologic cancer testing, expanding its clinical genetic-testing menu into blood cancers. › Launched two new germline assays for hematologic cancer testing, expanding its clinical genetic-testing menu into blood cancers. 2026-01 · source Introduced a curated cardiomyopathy and arrhythmia gene panel limited to genes with strong evidence, a more clinically focused cardiac test. 2025-08 · source Highlighted its combined short- and long-read whole-genome sequencing approach for detecting repeat-expansion neurological disorders, a technical differentiator. 2025-03 · source Source: company newsroom Raised additional $36M (Apr 2024) › Investors included Peregrine Ventures, Pitango HealthTech, New Era Capital Partners, and Bosch Ventures. · 2024-04-26 “secured an additional $36 million in funding from its portfolio of investors which includes Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures.” Source: funding announcement Currently hiring › Source: careers page	Poster Fri Oct 23 2:30 pm Part of Laboratory Genetics and Genomics Poster Friday Session Maximizing Diagnostic Yield in Rare Disease: A Comprehensive Analysis of 23,543 Genomic Cases Exhibit & Poster Hall · Board 2048F BioinformaticsClinical geneticsDiagnosticsGenetic testing

Organization

ASHG 2026 Attendance

Variantyx

Framingham, Massachusetts

1 VP Product

Private company

Variantyx provides whole-genome-based diagnostic and screening tests for rare disorders, reproductive genetics, hereditary cancer, and wellness.

Launched two new germline assays for hematologic cancer testing, expanding its clinical genetic-testing menu into blood cancers.

›

Launched two new germline assays for hematologic cancer testing, expanding its clinical genetic-testing menu into blood cancers.

2026-01 · source

Introduced a curated cardiomyopathy and arrhythmia gene panel limited to genes with strong evidence, a more clinically focused cardiac test.

2025-08 · source

Highlighted its combined short- and long-read whole-genome sequencing approach for detecting repeat-expansion neurological disorders, a technical differentiator.

2025-03 · source

Source: company newsroom

Raised additional $36M (Apr 2024)

›

Investors included Peregrine Ventures, Pitango HealthTech, New Era Capital Partners, and Bosch Ventures. · 2024-04-26

“secured an additional $36 million in funding from its portfolio of investors which includes Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures.”

Source: funding announcement

Currently hiring

›

Source: careers page

Poster

Fri Oct 23
2:30 pm

Part of Laboratory Genetics and Genomics Poster Friday Session

Maximizing Diagnostic Yield in Rare Disease: A Comprehensive Analysis of 23,543 Genomic Cases

Exhibit & Poster Hall · Board 2048F

BioinformaticsClinical geneticsDiagnosticsGenetic testing